文献速递胃肠外科围术期管理与 ERAS

术前抑郁严重程度与抗抑郁药对减重手术结局的影响

Impact of preoperative depression severity and antidepressant medication use on perioperative outcomes and long-term weight loss following primary bariatric surgery.
PubMed 文献 · Surg Endosc · 2026-07-09

该回顾性队列研究纳入2018年1月至2024年6月单中心930例首次微创袖状胃切除或Roux-en-Y胃旁路术患者,评估术前抑郁严重程度(PHQ-9)及抗抑郁药使用与围术期结局和长期减重的关系。结果显示抑郁患者术后6、12、24个月%EBWL更高,抑郁诊断或PHQ-9分级与30天并发症无显著差异,但抑郁患者未用抗抑郁药者总体并发症率和30天再入院率显著更高。

要点

  • 术前抑郁不是减重手术禁忌,抑郁患者短期减重效果良好。
  • 抑郁患者未用抗抑郁药者总体并发症率和30天再入院率更高。
  • 抑郁诊断或PHQ-9严重程度与30天围术期并发症无显著差异。

核心结论

  • 术前抑郁不是减重手术的禁忌证,抑郁患者可获得良好的短期减重效果,尤其在术后前两年。
  • 优化术前抑郁治疗可能降低围术期并发症,并对围术期结局有保护作用。

研究设计与样本

  • 回顾性队列研究,纳入2018年1月至2024年6月单中心930例首次微创袖状胃切除或Roux-en-Y胃旁路术患者。
  • 抑郁严重程度采用术前标准心理评估中的PHQ-9评分分层,抗抑郁药按药理类别和同时使用数量分类。

主要发现

  • 930例中128例(13.8%)有术前抑郁诊断。
  • 抑郁患者相比无抑郁患者,6个月%EBWL为46.9% vs. 43.1%(p=0.026),1年为56.9% vs. 52.0%(p=0.012),2年为59.0% vs. 50.4%(p=0.007),更晚时间点无显著差异。
  • 抑郁患者中,PHQ-9无/极轻组1年%EBWL显著高于轻/中度和中重度/重度组(p=0.031)。
  • 抑郁诊断或PHQ-9严重程度分类与30天围术期并发症无显著差异。
  • 抑郁患者中未用抗抑郁药者相比用药者,总体并发症率更高(11.5% vs. 0%,p=0.002),30天再入院率更高(15.4% vs. 3.0%,p=0.045)。

临床怎么用

  • 术前应评估抑郁严重程度并优化抗抑郁治疗,抑郁不应作为减重手术的排除标准。
  • 对抑郁患者尤其未用抗抑郁药者,应加强围术期并发症监测和再入院风险防范。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression affects up to half of bariatric surgery candidates, yet the impact of depression severity and preoperative antidepressant pharmacotherapy use on surgical outcomes remains poorly characterized. METHODS: This was a retrospective cohort study of patients who underwent primary minimally invasive sleeve gastrectomy or Roux-en-Y gastric bypass at a single institution between January 2018 and June 2024. Depression severity was stratified using PHQ-9 scores obtained during standard preoperative psychological evaluation. Antidepressant use was classified by pharmacologic class and number of concurrent medications. The primary outcome was percent excess body weight loss (%EBWL) at 6, 12, 24, 36, 48, and 60 months postoperatively. Secondary outcomes included 30-day perioperative complications, readmissions, and emergency department visits. RESULTS: Of 930 patients identified, 128 (13.8%) carried a preoperative depression diagnosis. Patients with depression achieved significantly greater %EBWL at 6 months (46.9% vs. 43.1%, p = 0.026), 1 year (56.9% vs. 52.0%, p = 0.012), and 2 years (59.0% vs. 50.4%, p = 0.007) compared to those without depression, with no significant differences at later timepoints. Among patients with depression, those with none/minimal PHQ-9 severity had significantly greater %EBWL at 1 year compared to mild/moderate and moderately severe/severe groups (p = 0.031). No significant differences in 30-day perioperative complications were observed based on depression diagnosis or PHQ-9 severity category. However, patients with depression who were not taking antidepressants had significantly higher overall complication rates (11.5% vs. 0%, p = 0.002) and 30-day readmission rates (15.4% vs. 3.0%, p = 0.045) compared to those receiving antidepressant therapy. CONCLUSIONS: Preoperative depression is not a contraindication to bariatric surgery; patients with depression can achieve excellent short-term weight loss, particularly in the first two postoperative years. Optimizing preoperative depression treatment appears to reduce perioperative morbidity and may confer a protective effect on perioperative outcomes in this population.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Maric E, Wang C, Zukancic S, et al. Impact of preoperative depression severity and antidepressant medication use on perioperative outcomes and long-term weight loss following primary bariatric surgery. Surg Endosc. 2026. PMID: 42426388. doi:10.1007/s00464-026-12943-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。